2020 年第 1 期 第 15 卷

2014—2018年我国七城市二肽基肽酶Ⅳ抑制剂和胰高血糖素样肽1受体激动剂及钠-葡萄糖共转运蛋白2抑制剂使用情况调查

Analysis of dipeptidyl peptidase Ⅳ inhibitor, glucagon-like peptide 1 receptor agonist and sodium-glucose co-transporter 2 inhibitor in 7 cities in China from 2014 to 2018

作者：周洋石秀锦彭文星林阳魏娟娟方振威

英文作者：

单位：首都医科大学附属北京安贞医院药事部100029

英文单位：

关键词：二肽基肽酶Ⅳ抑制剂；胰高血糖素样肽1受体激动剂；钠-葡萄糖共转运蛋白2抑制剂；降糖药；使用现状

英文关键词：

• 摘要：

• 【摘要】目的    通过调查我国7个城市二肽基肽酶Ⅳ抑制剂（DPP-4i）和胰高血糖素样肽1受体激动剂（GLP-1RA）及钠-葡萄糖共转运蛋白2抑制剂（SGLT2i）的使用情况及用药趋势，为促进药物合理使用提供基础参考数据。方法    数据来源于2014年1月至2018年12月中国药学会医院药学专业委员会“医院处方分析合作项目”收集的我国7个城市中87家各级样本医疗卫生机构的抽样处方，对患者用药情况进行分析。结果    5年来，7个城市DPP-4i，GLP-1RA，SGLT2i这3类降糖药物的销售金额呈逐年上升趋势，2018年药品销售金额中，DPP-4i（1 643.81万元）＞GLP-1RA（394.56万元）＞SGLT2i（48.23万元）。药品销售金额排名前5位分别为西格列汀（828.63万元）、沙格列汀（393.12万元）、利拉鲁肽（375.97万元）、维格列汀（188.15万元）、利格列汀（131.15万元）。结论    2014—2018年我国7城市DPP-4i、GLP-1RA和SGLT2i这3类新型降糖药物的使用较为合理，临床治疗中医师优先选择疗效和经济性较好的品种。

• 【Abstract】Objective    To investigate the usage of dipeptidyl peptidase Ⅳ inhibitor(DPP-4i), glucagon-like peptide 1 receptor agonist(GLP-1RA) and sodium-glucose co-transporter 2 inhibitor(SGLT2i) in 7 cities in China, in order to provide reference data for promoting the rational use of hypoglycemic drugs. Methods    Prescription data were collected from 87 medical and health institutions in 7 cities under the management of "the Hospital Prescriptions Cooperation Project" of Hospital Pharmacy Committee of Chinese Pharmaceutical Association from January 2014 to December 2018. Use of DPP-4i, GLP-1RA and SGLT2i was analyzed. Results    During the 5 years, the sales amounts of DPP4-i, GLP-1RA and SGLT2i in the 7 cities were increasing. In 2018, the sales amount was 16 438.1 thousand yuan of DPP-4i, 3 945.6 thousand yuan of GLP-1RA and 482.3 thousand yuan of SGLT2i. The top 5 drugs were sitagliptin(8 286.3 thousand yuan), saxagliptin(3 931.2 thousand yuan), liraglutide(3 759.7 thousand yuan), vildagliptin(1 881.5 thousand yuan) and linagliptin(1 311.5 thousand yuan). Conclusions    The use of three new types of hypoglycemic drugs including DPP-4i, GLP-1RA and SGLT2i was rational in 7 cities in China from 2014 to 2018. In clinical practice, physicians prefer the medication choice with high cost-effectiveness.